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Abstract 
Background Bullous pemphigoid (BP) is the most frequent autoimmune blistering 
dermatosis. Recently, the development of BP in patients treated with gliptins, also known as 
DPP-4 inhibitors, alone or in association with metformin has been outlined in case reports. A 
possible mechanistic explanation that links gliptins with BP comes from the findings that 
DPP-4 inhibition enhances the activity of proinflammatory eotaxin chemokine and promotes 
eosinophil activation in the skin, which is known to contribute to blister formation in BP. 
Objective To investigate a potential role of the gliptins in the development of BP in patients 
at the department of Dermatology of the University Hospital in Lausanne. 
Methods We reviewed all patients with BP diagnosed at the University Hospital of Lausanne 
(CHUV) between January 2007 and July 2013 (n= 93). We assessed the causal relationship 
between BP development and the intake of gliptins for each patient according to the World 
Health Organization and Uppsala Monitoring Centre (WHO-UMC) scale, a standardised 
causality assessment scale of adverse drug reactions. We compared our results with the 
existing literature.  
Results The yearly number of BP cases increased between 2007 and 2013. 23/93 BP 
patients had type 2 diabetes. The proportion of diabetic patients treated with gliptins in our 
study was 9/23 (39%) which is higher than the estimated proportion of patients treated with 
gliptins among the diabetic population (10-20%). In all nine cases, the causal relationship 
between drug intake and BP onset was classified as "possible", according to the WHO-UMC 
scale, which represents a probability less than 50% for BP to cause the disease.  
Conclusion Our study shows a weak but possible correlation between gliptins intake and BP 
development. Thus gliptins may entertain the disease or unmask a subclinical disease in 
predisposed individuals. We must be aware of this potential dermatological side effect and 
have to evaluate diabetic patients to benefit from this drug with very good tolerability and few 
side effects. Studies on a larger scale are needed to further elucidate the mechanisms that 
would confirm the role of gliptins in the pathogenesis of bullous pemphigoid. 
Keywords bullous pemphigoid, dipeptidyl-peptidase IV inhibitors, gliptins 
Abbreviations: BP: bullous pemphigoid, CHUV: Centre Hospitalier Universitaire Vaudois, 
University Hospital of Lausanne, DIF: direct immunofluorescence, DPP-4: dipeptidyl-
peptidase IV, GIP: glucose insulotropic peptide, GLP-1: glucagon-like peptide 1, IIF: indirect 
immunofluorescence, SSED-SGED: Société Suisse d'Endocrinologie et Diabétologie- 
Schweizerische Gesellschaft für Endokrinologie und Diabetologie. 
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1. Introduction 
 
Bullous pemphigoid (BP) is the most frequent autoimmune blistering dermatosis. It is 
characterized by the synthesis of autoantibodies against two proteins, BP180 and BP2301, 
also known as BPAG2 and BPAG1 respectively. Recently, the development of BP in patients 
treated with inhibitors of the dipeptidyl-peptidase IV (DPP-4/CD26) alone or in association 
with metformin has been outlined in case reports2,3,4,5. A possible mechanistic explanation 
that links gliptins with BP comes from the findings that DPP-4 inhibition enhances the activity 
of proinflammatory eotaxin chemokine6 and promotes eosinophil activation in the skin, which 
is known to contribute to blister formation in BP7,8. 
Inhibitors of the DPP-4, known as gliptins, have been introduced in the oral treatment of type 
2 diabetes in 2007 in Switzerland. Gliptins increase the secretion of insulin, through inhibition 
of the DPP-4 mediated catabolism of glucose-dependent insulinotropic peptide (GIP) and 
glucagon-like peptide-1 (GLP-1)9.  
 
Due to the recent introduction of the DPP-4 inhibitors, their potential dermatological side 
effects have not been studied yet in the Swiss dermatological population. We investigated 
BP patients with diabetes in the department of Dermatology of the University Hospital 
(CHUV) in Lausanne since 2007 in order to identify a potential role of gliptins in the 
development of BP in this population. 
 
2. Method  
 
We conducted a clinical retrospective study. After a review of the literature we identified the 
patients diagnosed with BP in the department of Dermatology of the University Hospital in 
Lausanne between January 2007 and July 2013, thanks to the Diamic analysis system of the 
laboratory of pathology. The research system provided a list of all histopathological reports 
with the keyword «bullous pemphigoid» (n= 483). After selecting the cases where a BP 
diagnosis was retained (n= 93), we completed the search with the help of the clinical record 
to confirm that this diagnosis had been clinically retained, and to identify the cases that  had 
type 2 diabetes (n= 23) treated with gliptins (n= 9). The files of the diabetic patients with BP 
were analyzed regarding: the diagnostic criteria reported for these cases: clinical, standard 
histological and immunofluorescence elements10; the antidiabetic treatment(s) received; the 
comorbidities and their treatments; the medical history of skin diseases. If a gliptin was 
mentioned in the medical record, we examined the chronology between BP diagnosis, 
treatment and onset and duration of the antidiabetic treatment(s). The missing data were 
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collected by contacting the concerned patients, their general practitioner and/or their 
chemist's. We assessed the causal relationship between BP development and the intake of 
gliptins for each patient according to the World Health Organization and Uppsala Monitoring 
Centre (WHO-UMC) scale11. It took into account the chronology between the suspect drug 
intake and the disease onset, reaction to drug discontinuation or rechallenge, plausibly 
involved concurrent drugs or diseases and supporting physiopathological evidence from the 
literature. The WHO-UMC scale does not give an accurate quantitative measurement of the 
correlation likelihood but classifies each case on a scale as "certain", "probable/likely", 
"possible", "unlikely" or "unclassified/unclassifiable". "Probable" and "possible" respectively 
correspond to a correlation likelihood of >50% and <50%. A statistical analysis was 
conducted, comparing the proportion of patients with BP and diabetes treated with gliptins to 
the proportion of the global diabetic population treated with gliptins. We also examined the 
evolution of the number of new cases diagnosed per year in the dermatological population of 
the University Hospital in Lausanne, to see whether there was a rise in the yearly number of 
BP cases with the increasing use of gliptins. Finally we compared our results with the 
existing literature. 
 
3. Results 
 
From January 2007 to July 2013, 93 patients were diagnosed with BP. Among these, 23 
were diabetic and nine were treated with gliptins. The patients included in the study 
presented a clear diagnosis of BP based on typical diagnostic criteria: the clinical 
presentation, a matching lesion on the skin histopathology report and a positive direct 
immunofluorescence (DIF). In some cases, indirect immunofluorescence (IIF) and/or 
autoantibody (BP180 and BP230) dosage by ELISA confirmed the diagnosis. Patients 
developed BP between five months and four years after the introduction of the gliptin. In all 
nine cases, the causal relationship between drug intake and BP onset was classified as 
"possible", according to the WHO-UMC scale11, which represents a probability less than 50% 
for BP to cause the disease. We describe each case's characteristics separately in Table 1.  
 
The estimated proportion of diabetic patients treated with gliptins among the general diabetic 
population is 10 to 20% (source: department of Endocrinology, CHUV and Swiss society of 
endocrinology and diabetology (SSED-SGED)). 
 
The distribution per year of the data we collected is listed in Table 2. 
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4. Discussion 
 
In the Swiss population, BP has an incidence of 12.1 new cases per 1 million people per year 
and most cases arise without any identified etiology12. Chronic use of several drugs is known 
to be associated with the development of BP, especially spironolactone, phenothiazines13,14 
and recently gliptins. Drug-induced and idiopathic BP are indistinguishable clinically or 
histopathologically3.  
All our BP cases arose after the introduction of the gliptin treatment (with variable elapsed 
time), which is in favor of a causality relationship between the drug use and BP development. 
Drug-withdrawal was tested in two patients without significant improvement. One patient had 
a gliptin discontinued two years before he developed BP. Discontinuation of the gliptin was 
not tested for the six remaining patients. The antidiabetic medications of patients n°3 and n°5 
were stopped on suspected drug-induced and gliptin-induced BP respectively. Even though 
patient n°3 had a quick favorable outcome without active lesion a few days after the 
interruption of his medication, a confounding factor is the rapid introduction of corticoids after 
the first symptoms. Therefore we cannot differentiate the respective influences of stopping 
the medication versus introducing an immunosuppressive therapy. Stable remission 
persisted despite reintroduction of the gliptin. This could be considered as a negative 
rechallenge. Regarding patient n°5, since there was no drastic change in the course of the 
disease after interruption of the gliptin, it is also difficult to assess its role in the pathogenesis 
of BP. He was already stable for a year on weekly methotrexate before the gliptin was 
stopped. The occasional pruritic symptoms of the patient are still present on methotrexate. It 
is also difficult to assess whether this mild pruritus is a residual BP symptom or a simple 
xerodermia with no specific pathophysiological mechanism implied.  
 
Moreover, three patients (n°7, n°8 and n°9) showed sustained remission without BP 
treatment for respectively 6, 30 and 36 months even though they were still on gliptins, what 
speaks against a role of this medication in PB pathogenesis. None of our patients showed 
BP resistant to conventional immunosuppressive therapy. It is important to notice that none 
of the cases was classified as "unlikely", so we cannot exclude that gliptins are implicated in 
BP development. A confounding factor is that BP is a heterogeneous disease lasting from a 
few months to years. It has a frequent chronic course with spontaneous exacerbations and 
remissions15. Most patients achieve remission but relapses occur in almost 10% of the 
cases16,17. Gliptins might entertain BP in predisposed individuals, with very variable delay or 
unmask a subclinical disease. Even though the medication is maintained, it does not 
specifically promote relapses once the patient is cured. 
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An interesting fact to be noted is the type of gliptin incriminated in our study and in former 
reports. In the Skandalis and al. study, four patients were on vildagliptin plus metformin 
combination and one patient was on sitagliptin plus metformin combination. Three cases 
were classified as "possible" according to the WHO-UMC assessment scale and two (among 
the vildagliptin plus metformin group) as "probable/likely". In our study, five patients out of 
nine were on vildagliptin alone or in combination with metformin, three on sitagliptin alone or 
in combination with metformin and one on vildagliptin plus metformin later replaced by 
sitagliptin plus metformin combination. It is interesting to note that no other type of gliptin 
(alogliptin, linagliptin, saxagliptin) was involved in a suspect case of gliptin-induced BP, 
included in other case-reports2,3,4,5. Vildagliptin is the most frequently incriminated DPP-4 
inhibitor. This may result from its popular use (it was the second gliptin to be approved by the 
American Food and Drug Administration in 2007 after sitagliptin18) or another yet unexplored 
mechanism due to its specific pharmacological properties. 
 
The proportion of diabetic patients treated with gliptins in our study was 39% (9/23). This is 
significantly higher compared to the estimated proportion of diabetic patients treated with 
gliptins among the general diabetic population: 10 to 20% (source: department of 
Endocrinology, CHUV and the SSED-SGED). The large proportion of patients on gliptins in 
our study may be explained either by an implication of the gliptin, the advanced age and 
multiple comorbidities of the population studied, or a combination of these factors. Our 
population of patients had a mean age of 77.6 years, which is also the typical age of BP 
onset12,14. This older population has more comorbidities than the general population and may 
have less equilibrated diabetes requiring a 2nd-line treatment like a gliptin. In summary, more 
patients were treated with gliptins in the population studied than in the non-BP diabetic 
population of similar age, what is rather in favor of a gliptin-BP correlation. 
In our study, 25% of the patients were diabetic, compared to the general population where 
the incidence of diabetes in patients over 75 years is approximately 18% in men and 8% in 
women19. Diabetes is thought to have a higher rate in BP patients than in the general 
population20,21 and our results confirm this statement. 
 
We observed an increasing number of BP in our population between 2007 and 2013 (Table 
2). This might be explained by an increase in the incidence of BP due to the ageing of the 
general population or by improved diagnostic performances22. A bias to be considered is that 
we only reported the patients biopsied and diagnosed at the CHUV, and a referral bias 
cannot be excluded. The increasing use of gliptins over the years may also be involved. It is 
interesting to note this evolution but the population studied is not large enough to make any 
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conclusion.  
Apart from clinical case reports about possibly gliptin-induced cases2,3,4,5, dermatological 
adverse reactions described as blistering-necrotic skin lesions were reported in monkeys 
during gliptins preclinical trials23. We did not consider a potential role of metformin in BP 
onset because there is no report of any adverse skin reaction due to metformin in the 
literature. Gliptins themselves do not seem to interact with other drugs by modifying their 
pharmacokinetic profile, except for saxagliptin, which is metabolized in the liver to an active 
metabolite by CYP3A4/524.  
Different physiopathological mechanisms could support a link between gliptins and the 
development of BP. DPP-4 has several functions as a regulatory protease involved in the 
digestion of cytokines, chemokines and growth factors, a binding protein for extracellular 
matrix components like collagen I and III, a costimulatory molecule for lymphocytes (T 
regulatory and T helper lymphocytes) and a receptor associated with CD45, an antigen 
expressed on all leucocytes25. The drug may act as a BP trigger by inhibiting the usual DPP-
4 enzymatic function that reduces the proinflammatory activity of chemokines, as eotaxin26 
and thus promoting eosinophil activation in the skin27, which is known to contribute to blister 
formation in BP28, 29. 
By contrast, other studies suggest that DPP-4 inhibitors could even protect from autoimmune 
diseases30,31,. In fact, the level of DPP-4 was found to correlate with the severity of some 
autoimmune diseases32 and a decreased level of DPP-4 induces a rise in anti-inflammatory 
TGFβ secretion from T cells30. These different theories show that the precise mechanisms 
that link gliptins to the development of BP are not fully elucidated yet.  
 
5. Conclusion 
 
This is the first study to investigate the potential dermatological side effects of gliptins in the 
Swiss population. We reviewed the BP patients biopsied at the University Hospital of 
Lausanne for the past 6 years. This selection process did not include the patients biopsied 
before consulting at the University Hospital and the patients seen in private practice 
dermatologists. We cannot assess whether our results are representative of the whole BP 
population. 
Although diagnostic delay in BP is thought to have no impact on prognosis33, its morbidity 
has an impact on the quality of life of the patients. Our study shows a weak but possible 
relationship between gliptins intake and BP development. It confirms that we must be aware 
of gliptins' potential side effects and detect, investigate and treat a potential skin reaction 
early, without preventing diabetic patients to benefit from a drug with very good tolerability 
and few side effects compared to other antidiabetic medications34. Studies on a larger scale 
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are needed to further elucidate the mechanisms that would confirm the role of gliptins in the 
pathogenesis of bullous pemphigoid.  
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Appendix 
Table 1. BP in type-2 diabetes patients treated with DPP-4 inhibitors. 
Patient 
No./Gender/
Age at BP 
onset 
[years] 
 
 
Gliptin type 
Gliptin 
present 
at BP 
onset 
[yes/no] 
Period of 
gliptin use 
before BP 
onset 
[months] 
 
 
BP outcome 
Gliptin 
present 
at last 
follow-up 
[yes/no] 
Relevant 
comorbidities and 
concurrent 
treatments9,10,11 
 
Level of causality 
of drug-induction 
of BP8 
 
1/M/70 
VildagliptinA 
Vildagliptin/MetforminB 
Saxagliptin/Metformin 
 
Yes 
 
12 Asymptomatic on MTX 10 mg/w at 6m 
follow-up 
 
Yes 
 
- 
 
Possible 
 
2/F/84 
 
Sitagliptin/Metformin 
 
Yes 
 
36 
Occasional pruritus on intermittent oral 
treatment (doxycycline, nicotinamide) at 
8m follow-up. 
 
Yes 
 
- 
 
Possible 
 
3/M/73 
 
Vildagliptin 
 
Yes 
 
> 48 
Dermocorticoids withdrawal 7m after BP 
onset. Occasional pruritus since then at 
1y follow-up. 
 
Yes 
 
- 
 
Possible 
 
 
4/F/70 
 
 
Vildagliptin/Metformin 
 
 
Yes 
 
 
5 
Dermocorticoids withdrawal 6m after BP 
onset. Relapsed  course 7m later rapidly 
responsive to dermocorticoids. 
Occasional pruritus and bullae sensitive 
to dermocorticoids at 1.5y follow-up. 
 
 
Yes 
 
 
- 
 
 
Possible 
 
5/M/68 
  
 
VildagliptinC 
Sitagliptin/Metformin 
 
Yes 
 
30 
 
Occasional pruritus on MTX 10 mg/w at 
1.5y follow-up. 
No. 
Stopped 
11m after 
BP onset. 
Dementia, 
seborrheic 
dermatitis. 
 
Possible 
 
6/M/80 
 
Sitagliptin 
 
No 
 
48 
 
Occasional pruritus on topical treatment 
(dermocorticoids 1x/w) at 2y follow-up. 
No. 
Stopped 
2y before 
BP onset. 
 
- 
 
Possible 
 
7/M/85 
 
Vildagliptin/Metformin 
 
Yes 
 
> 48 
Dermocorticoids withdrawal 2.5y after BP 
onset. Asymptomatic since then at 6m 
follow-up. 
 
Yes 
Eczema (gluteal 
fold), 
spironolactone. 
 
Possible 
 
8/M/93 
 
Vildagliptin 
 
Yes 
 
21 
Dermocorticoids withdrawal ~2m after BP 
onset. Asymptomatic since then without 
treatment at 2.5y follow-up. 
 
Yes 
 
- 
 
Possible 
 
 
9/M/76 
 
 
Sitagliptin 
 
 
Yes 
 
 
10-11 
Dermocorticoids interrupted after 1y. 
Relapsed course 2y later. 
Dermocorticoids withdrawal 4m after 
relapse. Asymptomatic since then at 3y 
follow-up. 
 
 
Yes 
 
Recent apparition 
of cognitive 
impairment. 
 
 
Possible 
A switched for vildagliptin/metformin after 6m. 
B switched for saxagliptin/metformin after 7m. 
C switched for sitagliptin/metformin after 31m. 
BP: bullous pemphigoid, F: female, M: male, MTX: methotrexate, m: month(s), w: week(s), y: year(s) 
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Table 2. Yearly number of BP cases from 2007 to July 2013. 
  BP cases 
 BP patients 
with diabetes 
BP patients with 
diabetes treated 
with a gliptin 
2007 20 3 0 
2008 8 1 0 
2009 9 1 0 
2010 13 3 1 
2011 13 4 2 
2012 18 6 3 
2013 (→ July) 12 5 3 
Total 93 23 9 
 
